Neurocrine, Depressed Over Major Depressive Disorder (NBIX, GSK)
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) just got a black eye. The company announced on Tuesday evening that its potential treatment for major depressive disorder was ineffective in a mid-stage study. The study on GSK561679, conducted with GlaxoSmithKline (NYSE: GSK), involved 150 patients and was lined up against and compared with a placebo.
This won’t make much difference now, but Neurocrine plans to hold a meeting with GlaxoSmithkline in the coming months after the full clinical data is avaialble and is reviewed. Then it will discuss the next steps for the program. Unfortunately, when drug trials are ineffective the next steps usually involve a handshake and a walking away.
The company further noted that CRF1 remains a difficult drug target for depression.
Shares closed at $6.25 on Tuesday and the after-hours session had shares down some 9.6% at $5.65 on more than 300,000 shares.
JON C. OGG
Comments
2 Responses to “Neurocrine, Depressed Over Major Depressive Disorder (NBIX, GSK)”
Leave a Reply
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders…
biotechnology training
It will be interesting to see if Neurocrine Biosciences’s stock price rebounds after further consideration of the data. stay tuned.